Tilray Shares Exhibit Continued Volatility Amid Strategic Shifts

Tilray shares swing amid Carlsberg partnership news. Q2 revenue up 3% but EPS miss. Analysts mostly rate Hold as stock is down 13% YTD.

Tilray Brands' stock continues to display a pattern of significant volatility. The cannabis and beverage group's shares have been oscillating between gains and losses following the mid-February announcement of a licensing partnership with Carlsberg. As of Wednesday, February 25, the equity declined by 1.1% to $7.83. Trading volume for the session was approximately 1.72 million shares, roughly 60% below the average. This movement followed a 4.9% advance on Tuesday, which itself came after a 2.6% drop on Monday.

Year-to-date, the stock records a loss of approximately 13.3%. Over the preceding twelve-month period, its trading range has spanned from $3.50 to $23.20, illustrating the extreme price swings characteristic of the cannabis sector. The company's current market capitalization stands at about $912 million.

Financial Performance Presents a Mixed Picture

The most recent quarterly results, for the second fiscal quarter of 2026 released on January 8, presented a dual narrative. Revenue increased by 3% to $217.5 million. However, the company reported a loss per share of $0.41, which fell substantially short of the $0.14 loss that was anticipated.

A breakdown reveals that international medical cannabis revenue grew by 36%, while adult-use cannabis sales in Canada rose by 6%. The distribution business, which includes Tilray Pharma, expanded by 26% to $85.3 million. In contrast, the beverage segment contracted sharply, declining by 20% to $50.1 million.

On a positive note, management highlighted that the company achieved a net cash position for the first time, amounting to roughly $30 million. Total cash, cash equivalents, and marketable securities are reported at $292 million. The subsequent quarterly earnings are scheduled for release on April 8, 2026.

Analyst Sentiment Remains Cautious

The prevailing consensus among market researchers is a "Hold" recommendation. Of eight current assessments, six advise "Hold," one suggests "Buy," and one recommends "Sell." In January, Roth MKM reduced its price target from $20 to $10 while maintaining a "Neutral" rating. Earlier in February, Zacks Research upgraded its stance from "Strong Sell" to "Hold." Coverage was initiated by Canaccord Genuity Group at the end of January with a "Hold" rating.

New Partnership with Carlsberg Outlined

On February 18, Tilray disclosed an exclusive, multi-year licensing agreement with the Carlsberg Group. Effective January 1, 2027, Tilray will gain the rights to produce, market, and distribute the Carlsberg, Carlsberg Elephant, 1664, and Kronenbourg 1664 Blanc beer brands within the United States. The initial term of the arrangement is five years, with an automatic extension for another five years provided certain performance metrics are met.

This agreement strengthens Tilray's standing as the fourth-largest craft beer brewer in the U.S. It represents a continuation of the company's strategy to grow its American beverage operations through partnerships with established brand portfolios.

Balancing Growth Initiatives and Challenges

The company now faces the dual challenge of successfully executing the new Carlsberg alliance while simultaneously stabilizing the declining performance of its existing beverage division. Although the international medical cannabis business is demonstrating growth, overall profitability remains negative. An additional overarching factor is the unresolved issue of federal cannabis regulation in the United States, a development that could prove pivotal for Tilray's medical cannabis ambitions.